Biotechnology company ImmunoMet Therapeutics Inc revealed on Monday the appointment of Dr Revati Shreeniwas as its chief medical officer.
As head of the medial department, Dr Shreeniwas will manage the clinical development programme for the company's lead investigational product Protein Complex 1 (PC1) inhibitor candidate, IM156, for idiopathic pulmonary fibrosis (IPF) and oncology indications.
Recently, Dr Shreeniwas has served on the faculty of Stanford University and Columbia Presbyterian Medical Center.
Previously, Dr Shreeniwas designed and implemented more than 50 US and international (Phase 1-4) clinical trials and been the clinical lead for regulatory interactions with the FDA and EMA.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT